Tanzeum
(Albiglutide)ApprovedPeptide
GSKAlbiglutide is used to help control blood sugar levels in people with type 2 diabetes. It works by helping the pancreas release more insulin when blood sugar is high.[2] Tanzeum is currently approved and in use across 6 indications[4].[1]
Tanzeum is one of 163 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.
6
Indications
29
Total Trials
0
Active Trials
162
Competitors
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Tanzeum
GSKApproved
Jardiance
Boehringer IngelheimPreclinical
NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Glargine
Eli LillyPreclinical
Aurlumyn
BBTG International Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Lovaza
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus10 trials
Show 7 more trials
Type 2 Diabetes8 trials
Show 5 more trials
Tics2 trials
Efficacy and Safety1 trial
6 more indications
Type 1 Diabetes Mellitus1 trial
Nausea1 trial
Safety and Efficacy1 trial
Oral1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tanzeum drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Albiglutide. EMBL-EBI & Wellcome Sanger Institute.
- [5]